uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
622.54 367.52 617.89 352.84 556.26 244.93 377.79 234.90 159.37 132.50
Receivables
5.86 5.88 4.19 102.38 58.77 6.62 0.95 0.23 1.59 9.18
Inventory
— — 12.02 6.92 — — — — — 0.48
Other current assets
7.08 7.61 2.66 2.81 2.68 3.02 0.75 0.33 0.69 1.27
Total current assets
655.99 390.29 651.85 476.77 628.24 258.91 384.21 236.58 162.78 143.95
Property, Plant, Equpment (Net)
13.80 20.42 46.55 50.53 43.51 32.33 28.77 29.18 34.28 35.70
Long-Term Investments
30.24 27.46 2.18 39.98 — 2.75 2.93 2.44 2.48 1.83
Goodwill and Intangible Assets (Total)
98.15 93.46 86.86 84.36 90.32 3.90 5.92 5.71 10.10 8.79
Long Term Assets (Tax, Deferred)
8.65 9.86 12.28 14.53 15.65 16.42 — — — —
Long-term assets (Other)
5.56 1.40 3.18 6.06 5.90 2.75 2.93 2.44 2.48 1.83
Total non-current assets
168.92 166.25 179.84 228.19 180.94 81.48 64.42 37.33 46.86 46.32
Total Assets
824.91 556.54 831.69 704.96 809.18 340.40 448.63 273.91 209.64 190.27
Accounts Payable
5.17 7.23 6.59 10.98 2.50 3.77 5.68 3.79 2.91 5.52
Accrued Expenses
41.29 29.23 30.53 30.57 28.49 18.04 12.46 8.23 8.84 9.77
Current Part of Debt
— — — — — — — 8.23 1.05 0.61
Current Revenue (Deferred)
— — — — — — 7.63 7.63 4.61 6.14
Other current liabilities
12.60 — 28.21 25.98 28.49 18.04 20.08 0.31 1.82 0.68
Total current liabilities
62.92 40.05 73.68 75.92 36.76 27.33 31.63 19.97 19.23 22.72
Long Term Debt (Total)
49.70 51.32 101.75 102.79 100.96 35.62 36.06 35.47 19.74 19.63
Non-current Revenue (Deferred)
— — — — — — 23.14 28.86 67.41 75.61
Long Term Tax Liability (Deferred)
7.97 7.04 7.54 8.26 12.91 (16.42) — 0.23 0.21 1.09
Non-current Liabilities (Other)
495.59 453.73 412.74 10.27 33.78 3.14 3.61 10.00 13.91 8.67
Total non-current liabilities
563.09 523.24 550.34 153.04 176.64 69.16 93.94 74.33 101.06 103.91
Total liabilities
626.01 563.29 624.02 228.96 213.40 96.49 125.57 94.30 120.29 126.63
Additional Paid In Capital
1,582.37 1,173.07 1,148.75 1,113.39 1,076.97 1,016.02 986.80 720.07 566.53 464.65
Common Stock (Net)
3.69 2.95 2.88 2.84 2.80 2.71 2.65 2.30 1.95 1.59
Retained Earnings
(1,328.94) (1,129.96) (890.41) (581.93) (455.14) (784.73) (659.71) (535.51) (475.32) (396.06)
Common Equity (Total)
198.90 (6.75) 207.67 476.01 595.78 243.91 323.06 179.61 89.36 63.63
Shareholders Equity (Total)
198.90 (6.75) 207.67 476.01 595.78 243.91 323.06 179.61 89.36 63.63
Shareholders Equity and Liabilities (Total)
824.91 556.54 831.69 704.96 809.18 340.40 448.63 273.91 209.64 190.27
Shares (Common)
62.34 48.99 47.83 46.97 46.30 44.78 43.71 37.35 31.34 25.26
Shareholders Equity (Tangible)
100.76 (100.21) 120.81 391.65 505.46 240.00 317.14 173.90 79.26 54.84
Net Debt
(572.84) (316.20) (516.14) (250.05) (455.29) (209.31) (341.73) (191.19) (138.58) (112.26)
Total Debt
49.70 51.32 101.75 102.79 100.96 35.62 36.06 43.70 20.79 20.24

Fold the line items

In millions of $ except per-share values · columns are period end dates